PolarityTE Inc. (NASDAQ: PTE)
You’re reading a free stock page from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
PolarityTE Inc. Returns vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
PolarityTE Inc. Company Info
commercial-stage biotechnology and regenerative biomaterials company focused on transforming the lives of patients by discovering, designing and developing a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering and material sciences. The PolarityTE platform technology begins with a small piece of the patients own, or autologous, healthy tissue, rather than artificially manipulated individual cells. From this small piece of healthy autologous tissue, the company creates an easily deployable, dynamic and self-propagating product designed to enhance and stimulate the patients own cells to regenerate the target tissues. Rather than manufacturing with synthetic and foreign materials within artificially engineered environments, PolarityTE manufactures with the patients own tissue and uses the patients own body to support the regenerative process to create the same tissue from which it was derived. PolarityTEs innovative method is intended to promote and accelerate growth of the patients tissues to undergo a form of effective regenerative healing.
News & Analysis
The company's stock had a huge week after announcing that Arches Research has signed a deal to use its coronavirus test kit.
Shares drop after the company announces that it is raising capital. Here are the must-know details for investors.
Shares plunge after the company reports fourth-quarter results. Here's what investors need to know.
Traders cheered after some positive regulatory news emerged.
The tiny biopharma found itself in the crosshairs of infamous short-seller Citron Research.
Find out which of these stocks got criticism from a famous short-seller.
The biopharma announced the pricing of a stock offering, but something seems off with this company.
Not every company is heading the wrong way on the bottom line this week.
Motley Fool Returns
Market-beating stocks from our award-winning analyst team.
Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/26/2022.
Discounted offers are only available to new members. Stock Advisor list price is $199 per year.
Calculated by Time-Weighted Return since 2002. Volatility profiles based on trailing-three-year calculations of the standard deviation of service investment returns.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.